Home > Publications database > Morbus Parkinson: Aktuelle Standards in Diagnostik und Therapie > print

001     201196
005     20210129215652.0
024 7 _ |a 10.1055/s-0032-1312738
|2 doi
024 7 _ |a 0015-8194
|2 ISSN
024 7 _ |a 0720-4299
|2 ISSN
024 7 _ |a 1439-3522
|2 ISSN
024 7 _ |a WOS:000310409200002
|2 WOS
024 7 _ |a altmetric:1290493
|2 altmetric
024 7 _ |a pmid:23033202
|2 pmid
037 _ _ |a FZJ-2015-03501
082 _ _ |a 610
100 1 _ |a Timmermann, L.
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Morbus Parkinson: Aktuelle Standards in Diagnostik und Therapie
260 _ _ |a Stuttgart [u.a.]
|c 2012
|b Thieme
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1434027577_12149
|2 PUB:(DE-HGF)
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|0 0
|2 EndNote
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a article
|2 DRIVER
520 _ _ |a Idiopathic Parkinson’s disease is still a clinical diagnosis. However, modern imaging and nuclear techniques allow very early diagnosis and lead to higher security in the differential diagnosis between idiopathic Parkinson’s disease and atypical Parkinson syndromes. At early stages of the disease, modification of disease progression and symptom control are key factors of the therapy. Continuous dopaminergic stimulation is even more important at later stages with first fluctuations. In stages where conservative medical options have been exhausted continuous pump therapies with Duodopa and apomorphine are attractive options. Deep brain stimulation in the subthalamic nucleus has turned out in the last years, especially in younger patients, to be a highly successful treatment option. Deep drain stimulation requires, however, a close preoperative work-up and individual consideration of potential effects and side effects.
536 _ _ |a 333 - Pathophysiological Mechanisms of Neurological and Psychiatric Diseases (POF2-333)
|0 G:(DE-HGF)POF2-333
|c POF2-333
|f POF II
|x 0
588 _ _ |a Dataset connected to CrossRef, juser.fz-juelich.de
700 1 _ |a Eggers, C.
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Salimi Dafsari, H.
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Pauls, K.
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Barbe, M.
|0 P:(DE-Juel1)131613
|b 4
|u fzj
773 _ _ |a 10.1055/s-0032-1312738
|g Vol. 80, no. 10, p. 560 - 569
|0 PERI:(DE-600)2037701-0
|n 10
|p 560 - 569
|t Fortschritte der Neurologie, Psychiatrie
|v 80
|y 2012
|x 1439-3522
909 C O |o oai:juser.fz-juelich.de:201196
|p VDB
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 4
|6 P:(DE-Juel1)131613
913 2 _ |a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|1 G:(DE-HGF)POF3-570
|0 G:(DE-HGF)POF3-572
|2 G:(DE-HGF)POF3-500
|v (Dys-)function and Plasticity
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Funktion und Dysfunktion des Nervensystems
|1 G:(DE-HGF)POF2-330
|0 G:(DE-HGF)POF2-333
|2 G:(DE-HGF)POF2-300
|v Pathophysiological Mechanisms of Neurological and Psychiatric Diseases
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF2
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21